These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The biological basis for immunotherapy in patients with chronic myelogenous leukemia. Pinilla-Ibarz J; Shah B; Dubovsky JA Cancer Control; 2009 Apr; 16(2):141-52. PubMed ID: 19337200 [TBL] [Abstract][Full Text] [Related]
3. Biological therapy and the immune system in patients with chronic myeloid leukemia. Rohon P Int J Hematol; 2012 Jul; 96(1):1-9. PubMed ID: 22661045 [TBL] [Abstract][Full Text] [Related]
4. Immunology and immunotherapy of chronic myeloid leukemia. Ilander M; Hekim C; Mustjoki S Curr Hematol Malig Rep; 2014 Mar; 9(1):17-23. PubMed ID: 24390549 [TBL] [Abstract][Full Text] [Related]
5. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Wong SF; Mirshahidi H Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900 [TBL] [Abstract][Full Text] [Related]
6. Novel approaches to therapy in CML. Bhatia R Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):115-120. PubMed ID: 29222245 [TBL] [Abstract][Full Text] [Related]
7. Immunology of chronic myeloid leukemia: current concepts and future goals. Vonka V; Petráčková M Expert Rev Clin Immunol; 2015 Apr; 11(4):511-22. PubMed ID: 25728856 [TBL] [Abstract][Full Text] [Related]
8. CML vaccines as a paradigm of the specific immunotherapy of cancer. Pinilla-Ibarz J; Cathcart K; Scheinberg DA Blood Rev; 2000 Jun; 14(2):111-20. PubMed ID: 11012250 [TBL] [Abstract][Full Text] [Related]
9. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Greiner J; Schmitt M Eur J Haematol; 2008 Jun; 80(6):461-8. PubMed ID: 18284627 [TBL] [Abstract][Full Text] [Related]
10. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia. Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787 [TBL] [Abstract][Full Text] [Related]
11. Treatment-free remission and immunity in chronic myeloid leukemia. Ureshino H Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Vonka V Immunotherapy; 2010 Mar; 2(2):227-41. PubMed ID: 20635930 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165 [TBL] [Abstract][Full Text] [Related]
17. Advances in immunotherapy of chronic myeloid leukemia CML. Held SA; Heine A; Mayer KT; Kapelle M; Wolf DG; Brossart P Curr Cancer Drug Targets; 2013 Sep; 13(7):768-74. PubMed ID: 23906051 [TBL] [Abstract][Full Text] [Related]